2m 2m 2m 2m 2m 2m 2m
Bionovate Techn (BIIO)
OTC
$0.0001+$0.00010 (+9,900.00%)
Price as of Jun 01, 2026- $7.00Market Cap
- 9,900.00%1-Year Change
- Medical DevicesIndustry
Bionovate Techn (BIIO)
$0.0001+$0.00010 (+9,900.00%)
Annual
Quarterly
06/30/2021 | 06/30/2020 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 0 N/A | 0 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 45,371 +37.26% | 33,055 N/A | |
Operating Profit | -45,371 +37.26% | -33,055 N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -60,937 -1.46% | -61,840 N/A | |
Interest Income and Expense and Net | -60,937 -1.46% | -61,840 N/A | |
Total Nonoperating Income and Expense | -61,173 -31.26% | -88,990 N/A | |
Income before Taxes | -106,544 -12.70% | -122,045 N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -106,544 -12.70% | -122,045 N/A | |
Net Income from Continuing Operations Applicable to Common | -106,544 -12.70% | -122,045 N/A | |
Basic EPS and Net Income | 0.00 N/A | 0.00 N/A | |
Diluted EPS and Net Income | 0.00 N/A | 0.00 N/A | |
Basic Weighted Average Shares | 45.1M +80.41% | 25.0M N/A | |
Diluted Weighted Average Shares | 45.1M +80.41% | 25.0M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 0 N/A | 0 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 0 N/A | 0 N/A | |
Total Current Assets | 0 N/A | 0 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | |
Total Assets | 0 N/A | 0 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 52,009 -77.03% | 226,400 N/A | |
Total Current Liabilities | 503,209 +26.86% | 396,665 N/A | |
Total Long-Term Debt | 185,375 0.00% | 185,375 N/A | |
Total Long-Term Liabilities | 0 N/A | 0 N/A | |
Total Liabilities | 503,209 +26.86% | 396,665 N/A | |
Retained Earnings | -2.8M +3.95% | -2.7M N/A | |
Total Stockholders Equity | -503,209 +26.86% | -396,665 N/A | |
Total Shares Outstanding | 7.8M -86.95% | 59.4M N/A | |
Cash Flow | |||
Cash from Operating Activities | 0 N/A | 0 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | N/A N/A | N/A N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | 33.49% N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.00 N/A | 0.00 N/A | |
Cash Ratio | 0.00 N/A | 0.00 N/A | |
Debt-to-Equity Ratio | -0.47 -54.56% | -1.04 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow